NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis $0.31 +0.00 (+0.54%) As of 10:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About GlucoTrack Stock (NASDAQ:GCTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GlucoTrack alerts:Sign Up Key Stats Today's Range$0.31▼$0.3450-Day Range$0.31▼$0.6752-Week Range$0.29▼$14.14Volume93,649 shsAverage Volume3.62 million shsMarket Capitalization$2.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey. Read More GlucoTrack Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreGCTK MarketRank™: GlucoTrack scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGlucoTrack has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGlucoTrack has only been the subject of 1 research reports in the past 90 days.Read more about GlucoTrack's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GlucoTrack is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlucoTrack is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlucoTrack has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.34% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 2.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently increased by 1.71%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlucoTrack does not currently pay a dividend.Dividend GrowthGlucoTrack does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.12 News SentimentGlucoTrack has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for GlucoTrack this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlucoTrack insiders have not sold or bought any company stock.Percentage Held by Insiders2.23% of the stock of GlucoTrack is held by insiders.Percentage Held by Institutions10.92% of the stock of GlucoTrack is held by institutions.Read more about GlucoTrack's insider trading history. Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GCTK Stock News HeadlinesCritical Analysis: Koninklijke Philips (NYSE:PHG) versus GlucoTrack (NASDAQ:GCTK)July 20, 2026 | americanbankingnews.comE.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for ...July 18, 2026 | finance.yahoo.comElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger. He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today.July 24 at 1:00 AM | Brownstone Research (Ad)Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and ...July 18, 2026 | markets.businessinsider.comGlucoTrack (GCTK) stock rallies 16% after hours: Here's what is going onJuly 18, 2026 | msn.comGlucoTrack (NASDAQ:GCTK) Stock Rating Lowered by Wall Street ZenJuly 18, 2026 | americanbankingnews.comE.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note FinancingJuly 17, 2026 | globenewswire.comGlucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets InitiativesJuly 17, 2026 | globenewswire.comSee More Headlines GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed this year? GlucoTrack's stock was trading at $3.87 at the beginning of the year. Since then, GCTK shares have decreased by 91.9% and is now trading at $0.3140. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) issued its quarterly earnings results on Thursday, August, 14th. The company reported ($9.62) earnings per share for the quarter. When did GlucoTrack's stock split? GlucoTrack's stock reverse split before market open on Tuesday, February 4th 2025.The 1-20 reverse split was announced on Thursday, January 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GlucoTrack own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlucoTrack investors own include Rolls-Royce Holdings PLC (RYCEY), Blink Charging (BLNK), Cameco (CCJ), Ford Motor (F) and iShares U.S. Infrastructure ETF (IFRA). Company Calendar Last Earnings8/14/2025Today7/24/2026AGM 20268/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 GCTK's financial health is in the Red zone, according to TradeSmith. GCTK has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:GCTK CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($18.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.39 million Net MarginsN/A Pretax MarginN/A Return on Equity-581.98% Return on Assets-220.10% Debt Debt-to-Equity Ratio0.08 Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.80 per share Price / Book0.11Miscellaneous Outstanding Shares7,720,000Free Float7,547,000Market Cap$2.42 million OptionableNot Optionable Beta0.77 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:GCTK) was last updated on 7/24/2026 by MarketBeat.com Staff. From Our PartnersTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | SponsoredA Wall Street Veteran's Weekly Options Strategy ExplainedA former Merrill Lynch and Vanguard advisor spent 25 years watching one weekly options play generate consisten...Base Camp Trading | SponsoredGoldman Sachs: 300 million jobs will disappearGoldman Sachs predicts 300 million jobs will disappear - and Elon Musk's 'Project Apex' AI supercomputer is ac...InvestorPlace | SponsoredElon's next move will be bigger than the IPO – and it could happen any day nowHedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning s...Brownstone Research | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredTwo paths to universal income. One already exists today.Robert Kiyosaki, author of Rich Dad Poor Dad, says there are two paths to Universal Basic Income - wait for El...Freedom Financial | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
